Nevro (NVRO) Expected to Announce Earnings on Wednesday

Nevro (NYSE:NVRO) is projected to post its quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect Nevro to post earnings of ($0.67) per share and revenue of $102.43 million for the quarter.

Nevro Price Performance

Shares of NYSE NVRO opened at $5.72 on Tuesday. The business’s 50 day moving average price is $4.48 and its two-hundred day moving average price is $4.98. The company has a market cap of $214.14 million, a PE ratio of -3.02 and a beta of 0.91. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67. Nevro has a twelve month low of $3.16 and a twelve month high of $17.63.

Wall Street Analysts Forecast Growth

NVRO has been the topic of several research reports. Morgan Stanley downgraded Nevro from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $9.00 to $4.00 in a research report on Monday, December 2nd. Canaccord Genuity Group upped their target price on Nevro from $4.00 to $5.85 and gave the company a “hold” rating in a research report on Friday, February 7th. StockNews.com started coverage on Nevro in a research report on Tuesday. They set a “hold” rating on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $7.00 price target on shares of Nevro in a research report on Tuesday, November 12th. Finally, Citigroup reduced their price target on Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.